Notice2021-24445
Prospective Grant of an Exclusive Patent License: Use of Tomentosenol in Treating or Preventing Skin Disorders
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 9, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University of the Sunshine Coast ("USC"), a public university based on the Sunshine Coast, Queensland, Australia, in its rights to the inventions and patents listed in the SUPPLEMENTARY INFORMATION section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 214 (Tuesday, November 9, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 214 (Tuesday, November 9, 2021)]
[Notices]
[Page 62190]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-24445]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Use of
Tomentosenol in Treating or Preventing Skin Disorders
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive, sublicensable patent license
to University of the Sunshine Coast (``USC''), a public university
based on the Sunshine Coast, Queensland, Australia, in its rights to
the inventions and patents listed in the SUPPLEMENTARY INFORMATION
section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before November 24, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Rose M. Freel, Ph.D., Senior Licensing and
Patenting Manager, NCI Technology Transfer Center, Telephone (301) 624-
8775 or Email: <a href="/cdn-cgi/l/email-protection#5c2e332f39723a2e3939301c323534723b332a"><span class="__cf_email__" data-cfemail="790b160a1c571f0b1c1c1539171011571e160f">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to USC:
Australian Provisional Patent Application No. 2021902329, filed Aug 3,
2021, entitled ``Use of tomentosenol in treating or preventing skin
disorders'' (HHS Ref. No. E-107-2021-0).
The patent rights in these inventions have been assigned to the
Government of the United States of America and the University of the
Sunshine Coast. The prospective patent license will be for the purpose
of consolidating the patent rights to USC, one of the co-owners of said
rights, for commercial development and marketing. Consolidation of
these co-owned rights is intended to expedite development of the
invention, consistent with the goals of the Bayh-Dole Act codified as
35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
USC will be subject to the provisions of 37 CFR part 401 and 404.
The invention pertains to tomentosenol A, a natural product that
may be useful for treating, inhibiting, or preventing scar formation
development or progression, reducing pre-existing scar tissue, and/or
other fibrotic skin disorders. Based on current available data, the
intended use for the invention is as a therapeutic in scar therapy,
skin fibrosis, skin diseases, and inhibition of the proliferation or
migration of skin cells.
This notice is made pursuant to 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license will include terms for the
sharing of royalty income with NCI from commercial sublicenses of the
patent rights and may be granted unless within fifteen (15) days from
the date of this published notice the NCI receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 3, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-24445 Filed 11-8-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 9, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.